source
- FDA leadership stabilizes under new CBER and CDER heads and appoints first AI deputy commissionerAt the Food and Drug Administration, Karim Mikhail and Michael Davis have been confirmed as the permanent heads of the Center for Biologics Evaluation and Research and the Center for Drug Evaluatio…
- Alzheon seeks up to $500M in new financing after Phase 3 setback for Alzheimer’s drugAlzheon, a biotech based in Framingham, Massachusetts, has been pursuing an Alzheimer’s therapy for more than a decade. Its lead candidate recently failed to achieve the primary goals in a Phase 3…